Lantheus Q2 Earnings Preview: Analyst Expectations and Potential Upside

Lantheus Holdings (LNTH) expects a decrease in EPS and revenue for Q2. Analysts predict a 74.66% upside, with an average target price of $127.62. GuruFocus estimates suggest a 50.65% potential growth from the current price. The company has a history of outperforming EPS expectations and exceeding revenue predictions.

Lantheus Holdings (LNTH), a leading radiopharmaceutical company, is set to release its second-quarter earnings report before the market opens on August 6, 2025. Analysts expect a decrease in earnings per share (EPS) and revenue for the quarter. The current EPS estimate stands at $1.68, representing a 6.7% year-over-year (YoY) decline, while the revenue estimate is $387.94 million, indicating a 1.6% YoY decrease [1][2].

Despite these anticipated declines, Lantheus has consistently outperformed EPS expectations 75% of the time and exceeded revenue predictions 88% of the time over the past two years. Recent revisions to EPS and revenue estimates show a mix of upward and downward adjustments, with three upward EPS revisions and ten downward ones, and one upward revenue revision and eleven downward ones [1][2].

Analysts are bullish on Lantheus, with an average one-year price target of $127.62, representing a potential 74.66% upside from the current trading price of $73.07. The high estimate is $159.00, and the low estimate is $109.00. The consensus recommendation from 13 brokerage firms is an "Outperform" rating, suggesting a Strong Buy [1].

GuruFocus estimates suggest a potential upside of 50.65% from the current price, with the projected GF Value set at $110.07 over the next year. The GF Value is an estimate of the stock's fair trading value, taking into account historical multiples and past business growth, alongside future performance projections [1].

Lantheus Holdings has shown signs of significant buying pressure, with its 15-minute chart triggering Bollinger Bands expanding upward and a KDJ Golden Cross scheduled for July 31, 2025, at 15:15. This indicates a potential shift in market trend, with a momentum shift towards the upside and potential for further price appreciation [3].

The company's recent financial performance has been robust, with an adjusted EPS of $1.70 in the latest quarter, surpassing market expectations of $1.56. Revenue also exceeded projections, reaching $378.734 million. Lantheus's radiopharmaceutical product, PYLARIFY, is expected to achieve sales exceeding $1 billion in 2024, further solidifying its position as a market leader [3].

Investors are advised to monitor Lantheus Holdings' earnings report and the company's ability to manage PYLARIFY's growth and forthcoming innovations. If successful, these moves could propel the company into new ventures and partnerships, cementing its standing in the competitive pharmaceutical sector.

References:
[1] https://www.gurufocus.com/news/3036739/lantheus-lnth-q2-earnings-preview-key-expectations-and-revisions
[2] https://seekingalpha.com/news/4478834-lantheus-holdings-q2-2025-earnings-preview
[3] https://www.ainvest.com/news/lantheus-holdings-15min-chart-shows-bollinger-bands-expanding-upward-kdj-golden-cross-2508/